Insight Molecular Diagnostics Inc. Common Stock (IMDX) — 分析摘要
Insight Molecular Diagnostics Inc. Common Stock（IMDX）的市值为148.21百万美元，最近一年的营收同比增长了+115.6%。净利润率为-1238.5%。当前市盈率为-3.1倍。
核心要点
- 营收同比变化+115.6%
- 净利润率-1238.5%
- 市盈率-3.1倍
与IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES板块的其他公司相比，IMDX的营收增长为+115.6%，市盈率为-3.1倍。
Insight Molecular Diagnostics Inc. Common Stock (IMDX)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -473.2x — 盈利不足以覆盖利息支出
营业利润率为 -2500.7% — 严重经营亏损
净利率为 -2454.6% — 亏损超过收入（可能含一次性费用）
营收较上一期下降 51.9%。
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
行业
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
员工人数
58
总部
NASHVILLE, TN
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。